Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Is an innovative pharmaceutical group enterprise that integrates scientific research, production & sales; a well-known R&D and production base for pharmaceuticals that work against hepatopathy & anti-tumor drugs; a national key high-tech enterprise; & a key backbone enterprise of the Lianyungang New Pharmaceutical Industry Base which operates under the National Torch Plan. It ranked 16th in the đứng đầu 100 enterprises in China's pharmaceutical industry in 2018 and was the best industrial enterprise in China's pharmaceutical R&D hàng hóa line in 2019 (selected và announced by the đài loan trung quốc National Pharmaceutical Industry Information Center).
Bạn đang xem: Chiatai tianqing pharma
CTTQ always regards scientific và technological innovation as an important strategy for corporate development, & it is one of the pharmaceutical companies that invest more in innovative pharmaceutical research in China. With the research institute as the innovation carrier, CTTQ has successively established high-level R&D platforms such as “Jiangsu new hepatopathy drug engineering technology research center”, “Post-doctoral scientific research working station”, “National enterprise giải pháp công nghệ center” và “Jiangsu key laboratory of research on antiviral targeted drugs”, & its independent innovation capability has been continuously enhanced.
With its corporate development and improvements in its R&D capabilities, the annual R&D investments of CTTQ accounts for 10-12% of annual sales revenue. At present, the company is researching 251 projects, including 74 innovative drugs, 146 generic drugs, và 31 biological drugs.
CTTQ has four production bases in Lianyungang. The preparation base has obtained the first new GMP certificate in China, and many production lines have passed the EU's cGMP certification & the USA's FDA certification. The acquisition of these certificates indicates that the enterprise's pharmaceutical production chất lượng and management cấp độ are at the forefront of the Chinese pharmaceutical industry.
CTTQ has six major series of products in the fields of oncology, hepatopathy, respiration, infection, endocrinology và cardiovascular and cerebrovascular diseases, and has more than đôi mươi products with annual sales of over 100 million Chinese Yuan, forming a “100 million Chinese Yuan sản phẩm group”. CTTQ has also formed a quality product line in the anti-tumor & hepatopathy fields. The first new type of drug (FTND), Anlotinib Hydrochloride capsules, is the standard drug for the three-line treatment of patients with advanced non-small cell lung cancer. The company has many hàng hóa lines that work against hematological tumors, and its products Decitabine (first generic), Imatinib (first generic), Dasatinib (first generic), Bortezomib, and Lenalidomide have all been put onto the market. The products that work against solid tumors, such as Capecitabine, Abiraterone, Gefitinib, etc., have also been put on the market. Respiration, antibiotics & other fields are the key directions for the future development of the enterprise. As for biological drugs, Rituximab injection, Bevacizumab injection, Adalimumab injection và Trastuzumab injection have all entered phase III clinical studies.
Xem thêm: Kiến Thức Các Loại Phong Cách Phong Cách Ngôn Ngữ Trong Văn Bản
With regards to its future development, CTTQ will continue khổng lồ maintain its leading position in the field of hepatic health, aiming at the cure of hepatitis B & contributing to lớn the global elimination of viral hepatitis by 2030. It shall also focus on creating innovative product lines in the fields of oncology & respiration, và shall promote the shift of the enterprise from “mainly against hepatopathy” to “two cores & multiple strengths”; from chemical drugs khổng lồ a “combination of chemical drugs và biological drugs”; from a “combination of innovative drugs và generic drugs” khổng lồ “being led by innovative drugs”; and from “focusing on China” lớn “coordinated development at home and abroad”. At the same time, it shall innovate its technological approach và business models khổng lồ promote the transformation and improvement of its hàng hóa R&D, production giải pháp công nghệ and sale models, thus making steady progress towards an innovative and internationalized pharmaceutical group.